test

Kenneth B Roberts MD

Professor of Therapeutic Radiology; Medical Director, Yale-New Haven Shoreline Medical Center, Department of Radiation Oncology; Associate Chief and Medical Director for Radiation Oncology at Shoreline Medical Center, Yale-New Haven Hospital

Clinical Interests

General radiation therapy; pediatric radiation therapy; hematologic malignancy; lymphoma; Hodgkin’s disease; total body irradiation; endovascular brachytherapy; oncologic brachytherapy; gynecologic cancer; cervix cancer; gastrointestinal cancer; colorectal cancer


Board Certifications

1995
Radiation Oncology, Board Certified
1987
Internal Medicine, Board Certified
1989
Medical Oncology, Board Certified

Patient Care Locations

kenneth_robertsfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Chordoma, Desmoid Tumor, Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, and Soft TissueA COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (COG 9902)
Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, and Lymphoid LeukemiaTreatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (AALL0932) (CIRB)
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma, and Brain and Nervous SystemANBL0032: PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (Ch14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
Cancer and Myeloid and Monocytic LeukemiaAAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for patients with High Allelic Ratio FLT3/ITD; A Groupwide II/III Study
Brain and Nervous SystemACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

More Clinical Trials...

Edit Profile